Enterprise Value
-62.64M
Cash
109.8M
Avg Qtr Burn
-16.98M
Short % of Float
9.26%
Insider Ownership
15.24%
Institutional Own.
86.91%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Milademetan (RAIN-32) Details Solid tumor/s, Cancer | Phase 2 Data readout | |
Milademetan (RAIN-32) w/ atezolizumab Details Solid tumor/s, Cancer | Failed Discontinued | |
Milademetan (Rain-32) Details Solid tumor/s, Cancer, Carcinoma , Metastatic merkel cell carcinoma | Failed Discontinued | |
Milademetan (Rain-32) Details Liposarcoma, Cancer, Solid tumor/s | Failed Discontinued |